| Serial Number | 97388326 |
| Word Mark | SERVING OVERLOOKED PATIENTS |
| Filing Date | Friday, April 29, 2022 |
| Status | 731 - SECOND EXTENSION - GRANTED |
| Status Date | Wednesday, February 21, 2024 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, February 21, 2023 |
| Goods and Services | pharmaceutical preparations sold as a kit for use by pharmacists and physicians in creating compounded hormone replacement medicines, topical anti-inflammatory and ultrasound gels, pain and gastrointestinal disorders treatment medicines, and anti-inflammatory, antimicrobial, and antifungal treatment medicines; medicines for the treatment of cardiovascular diseases and disorders, colitis, muscle spasm, infectious diseases, acid-reflux disease, ulcer disease, and urological disorders; antibiotics; pharmaceutical products for the treatment of pain, thyroid disorders, gastrointestinal disorders, gastroesophageal disorders, inflammation, infections, fungal diseases and disorders, cardiovascular diseases and disorders, colitis, muscle spasm, attention deficit hyperactivity disorders, infectious diseases, acid-reflux disease, ulcer disease, and urological disorders having vancomycin, enalapril, lisinopril, and methotrexate as the active pharmaceutical ingredient; antacids; muscle relaxants; hormone replacement medicines; topical anti-inflammatory and ultrasound gels; pharmaceutical preparation for the treatment of pain, thyroid disorders, gastrointestinal disorders, gastroesophageal disorders, inflammation, infections, fungal diseases and disorders, cardiovascular diseases and disorders, colitis, muscle spasm, attention deficit hyperactivity disorders, infectious diseases, acid-reflux disease, ulcer disease, and urological disorders; pharmaceuticals for use in the treatment of cancer and autoimmune diseases and disorders, and for the treatment and prevention of renal, oncological, inflammatory, gastrointestinal, gastroesophageal, and cardio-vascular diseases and disorders |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Wednesday, May 4, 2022 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | Azurity Pharmaceuticals, Inc. |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 03 - Corporation |
| Address | Woburn, MA 01801 |
| Party Name | Azurity Pharmaceuticals, Inc. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | Woburn, MA 01801 |
| Event Date | Event Description |
| Thursday, February 22, 2024 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Wednesday, February 21, 2024 | SOU EXTENSION 2 GRANTED |
| Wednesday, February 21, 2024 | SOU EXTENSION 2 FILED |
| Wednesday, February 21, 2024 | SOU TEAS EXTENSION RECEIVED |
| Tuesday, October 10, 2023 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Friday, October 6, 2023 | SOU EXTENSION 1 GRANTED |
| Friday, October 6, 2023 | SOU EXTENSION 1 FILED |
| Friday, October 6, 2023 | SOU TEAS EXTENSION RECEIVED |
| Tuesday, April 18, 2023 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| Tuesday, February 21, 2023 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Tuesday, February 21, 2023 | PUBLISHED FOR OPPOSITION |
| Wednesday, February 1, 2023 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Wednesday, January 18, 2023 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Tuesday, January 10, 2023 | ASSIGNED TO EXAMINER |
| Wednesday, May 4, 2022 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Tuesday, May 3, 2022 | NEW APPLICATION ENTERED |